Levophacetoperane: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
No edit summary
 
Line 29: Line 29:
[[Category:Norepinephrine-dopamine reuptake inhibitors]]
[[Category:Norepinephrine-dopamine reuptake inhibitors]]
{{Pharm-stub}}
{{Pharm-stub}}
{{No image}}
 
<gallery>
<gallery>
File:Phacetoperane chemical structure.png|Levophacetoperane
File:Phacetoperane chemical structure.png|Levophacetoperane
</gallery>
</gallery>

Latest revision as of 00:34, 17 March 2025

Levophacetoperane is a stimulant drug of the phenethylamine and amphetamine chemical classes. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). Levophacetoperane was previously used as an anorectic or weight loss drug, but has since been discontinued.

History[edit]

Levophacetoperane was first synthesized in the 1960s and was used as an anorectic in the treatment of obesity. However, due to concerns about potential for abuse and addiction, it was discontinued.

Pharmacology[edit]

Levophacetoperane acts primarily as a norepinephrine-dopamine reuptake inhibitor, meaning it increases the levels of the norepinephrine and dopamine neurotransmitters in the brain by inhibiting their reuptake into neurons. This results in increased neuronal activity, which can lead to increased alertness and decreased appetite.

Side Effects[edit]

The side effects of Levophacetoperane are similar to those of other stimulant drugs and can include insomnia, nervousness, increased heart rate, and increased blood pressure. In rare cases, it can also cause psychosis or other serious mental health issues.

Legal Status[edit]

Levophacetoperane is currently a controlled substance in many countries due to its potential for abuse and addiction. In the United States, it is classified as a Schedule II controlled substance under the Controlled Substances Act.

See Also[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!